#adcplatform — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #adcplatform, aggregated by home.social.
-
Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
#YonhapInfomax
#SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100156 -
Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
#YonhapInfomax
#SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100156 -
Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
#YonhapInfomax
#SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100156 -
Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.
#YonhapInfomax
#SamjinPharmaceutical #SJN314 #TechnologyTransfer #ChronicUrticaria #ADCPlatform
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100156 -
ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
#YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90894 -
ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
#YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90894 -
ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
#YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90894 -
ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
#YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90894